This round is no longer accepting investments, but hundreds just like it are live now.

Log In


Better Breathing, Better Health

After you stop breathing, it only takes 4 minutes for permanent brain damage to start. Surprisingly, this critical vital sign is poorly monitored, using bulky, wired systems based on technology conceived half a century ago. Makani Science’s novel, compact, and wireless system is poised to bring breathing monitoring to new heights, making this neglected vital sign easier to measure, and unlocking a multi-billion-dollar market. We are currently pre-revenue, pre-FDA clearance and our product is in pre-production.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$83,121.95 Raised


The Makani Science Respiration Monitor uses a completely novel sensor technology, unlike current monitors, and has the potential to become the new standard of care for this vital sign.

Our unique sensor has the potential to make breathing monitoring more accessible in many different wearable applications, tapping into lucrative multi-billion dollar markets increasing at a CAGR of 18.5% fueled by the rise of telehealth.*

Clinicians, potential strategic partners, and researchers have already expressed interest in our product and are excited by our technology and how it can improve the state of the industry.

*Information from Globe Newswire (Source)


Better Breathing, Better Health

*The above is a product still currently under development and is not yet available on the market.

The Makani Science Respiratory Monitor was developed to improve respiratory monitoring by making it:

  • More accurate (Directly Measure Breathing)
  • Convenient (Wireless and Compact)
  • Accessible (Easily Adaptable with Other Systems)
  • Comfortable (Soft and Flexible Sensor)
  • Easy to Use (Simple Interface)

We plan submit our premarket notification to the FDA early 2023 and hope to launch our product Q3 2023. We will target three major areas that would benefit from better respiratory monitoring:

  • Medical procedures where patient monitoring could be made safer by providing an earlier and more accurate alert for respiratory abnormalities.
  • Respiratory disease management by analyzing the breathing patterns of patients and telling them when they should be getting help will help to improve the patient's quality of life.
  • Breathing management in health, wellness, and fitness where feedback on the user's breathing can help improve their quality of life.

Makani Science is in the process of finalizing a licensing agreement with UC Irvine for the exclusive license to use their family of seven patents around the core sensor technology for monitoring breathing. Makani Science would be able to sublicense the technology, and payments and royalties would be made based on set milestones. UC Irvine would receive a small equity stake in Makani Science.

The Problem & Our solution

Wireless Technology for Better Monitoring of Breathing

It only takes 4 minutes for brain damage to occur after you stop breathing; death is almost guaranteed after 10 minutes. This means every second counts when a patient stops breathing.

It is a shocking reality that in the clinical setting, a vital sign as important as respiration is often poorly monitored. Breath rate is a neglected vital sign, mostly because current monitors, such as pulse oximetry and capnography, are inconvenient, bulky, inaccurate, or have delayed response times (Source | Source | Source). This has been a contributing factor to repeated, potentially preventable, patient complications every year. Outside of the hospital, there are very few wearable technologies that can measure breathing accurately, making this a vital sign relatively untapped.

Makani Science novel sensor component

Due to the unique features of the Makani Science sensor technology – novel, compact, postage-sized, and flexible – shown above, the Makani Science monitoring system overcomes these deficiencies, allowing for direct monitoring of breathing in a more accurate, convenient, and comfortable way. 

We believe that because of our unique sensor design and small form factor, the Makani Science Respiration Monitor has the potential to help improve the current state of the art in respiration monitoring and unlock breathing applications never before realized.

The animations above show the convenience of the Makani Science Respiration System, wireless and convenient. The product is still currently under development and is not yet available on the market.

the market & Our Traction

Growing Demand and Promising Technology

Source | Source


Our initial market will target procedures where patients are sedated, and their breathing may be at risk. Surprisingly, anesthesiologists are not always present to monitor these patients, and sadly, deaths have been repeatedly attributed to improper respiratory monitoring (Source). 

For this application, we believe the Makani Science Respiration Monitor can improve the safety of the patients and function as an early alert system for breathing abnormalities. This global anesthesia and respiratory device market is predicted to reach $38.2 billion by 2023 (Source).

Disease Management

Another critical area where the Makani Science Respiration Monitor could disrupt the market is in the disease management sector. There are many diseases that affect our breathing such as COPD, asthma, sleep apnea, and more recently COVID – to name a few. 

Responding quickly to changes in the patient's condition is essential for their health. The Makani Science Respiration Monitor could potentially track and manage patient breathing, improving their quality of life. The respiratory device for disease management market is predicted to reach $21.6 Billion by 2023 (Source).

Wellness and Mindfullness

In addition, the wellness, mindfulness, and fitness market have enormous potential for our sensor. As stress and anxiety increase in our society, we believe people will want to start managing their mental health through biofeedback and proper breathing control. 

We believe our sensor, in conjunction with the right App, will be the perfect platform to provide information to the user on how well they are breathing to optimize stress reduction (Source Source). The consumer health and wellness market is predicted to reach $55.8 Billion by 2023 (Source).

*The product is still currently under development and is not yet available on the market.

Source | Source | Source

Total Market

Due to its differentiating features of being small, flexible, and comfortable, the Makani Science sensor is suitable for wear in clinical settings or home use and can be incorporated into other sensors as well. In total, the potential market for all targeted areas could be over $100 Billion in 2023!

Our Traction and Testimonials

Makani Science has also been accepted into well-known accelerators including Y-Combinator and MedTech Innovators.

*The above testimonials may not be representative of the opinions of other medical experts or the experiences of other customers and is not a guarantee of future performance or success.

Why Invest

Monitoring a Critical Life-Sustaining Vital Sign with Opportunity for Expansion

*The product is still currently under development and is not yet available on the market.

Whether making sedated procedures safer, managing respiratory diseases, and potentially saving lives, the Makani Science Respiration Monitor can make a neglected vital sign more accessible to the world. 

With numerous applications for our product, we are presented with an opportunity to tap into this large multi-billion dollar space and can elevate it to new levels with the Makani Science Respiration Monitor, while saving and improving patient lives.

Join the movement toward better breathing and better health and invest in Makani Science today.

Code View


5270 California Ave Ste 300
Irvine, CA 92617

After you stop breathing, it only takes 4 minutes for permanent brain damage to start. Surprisingly, this critical vital sign is poorly monitored, using bulky, wired systems based on technology conceived half a century ago. Makani Science’s novel, compact, and wireless system is poised to bring breathing monitoring to new heights, making this neglected vital sign easier to measure, and unlocking a multi-billion-dollar market. We are currently pre-revenue, pre-FDA clearance and our product is in pre-production.


Michael Chu
Michael Chu
Co-Founder and CEO

Michael is one of the original founders of Makani Science. He completed his PhD at the University of California, Irvine, in Biomedical Engineering, where he co-authored over 10 peer-reviewed publications and is listed as an inventor on 3 patents. His research around wearable respiratory monitoring has been highlighted in various news and media outlets and serves as the foundational technology for Makani Science.

Michael has worked closely with the Makani Science team from day one to develop the Makani Science Respiratory Monitoring System. He has also actively participated in the business development side of the company, establishing partnerships for future collaborations and research opportunities.

Michael participated in Y-Combinator and MedTech Innovator as part of their 2021 summer cohort where he helped raised additional funding for the company. In Q4 of 2021, Michael was selected as the full time CEO for Makani Science.

Ray Chan

Ray Chan

Board Chairman

Ray Chan is a prominent investor who has been recognized as one of Orange County Business Journal’s most influential business leaders since 2017. Ray is the Managing Director of K5 Ventures and has been leading county-wide efforts to build the tech and startup ecosystem within Orange County. He is also an active member of Tech Coast Angels and an Investment Partner for their Angel Capital Entrepreneur Funds.

Ray has a 30+ year track record of successful business execution and of being a startup queen/kingmaker. Ray has personally made over 300 investments and is well-known for rewarding shareholders with exceptional financial returns.

 As the co-founder of Koa Accel and Managing Director of the Koa Accel Venture Fund, Ray is excited to combine all of his expertise and passions to transform life-saving MedTech ideas into thriving commercial ventures.

Greg Buchert

Greg Buchert

Board Director

Greg Buchert, MD, MPH is the CEO of GSB Health Management Solutions, a consulting firm focused on innovative solutions to improve the health care delivery system. He has over 25 years of C-Suite experience in health plan leadership roles and leverages that in his roles as advisor to startup companies. He is the former President and CEO of Blue Shield of California’s Promise Health Plan that serves over 500,000 Medicaid, Medicare and Dual Eligible members. He previously served as the Chief Executive Officer that launched Centene’s first Medicaid Managed Care Plan in California and later as Chief Medical Officer of HealthNet after its acquisition by Centene. 

Greg was a founding executive for CalOptima, a public managed care organization where he served as Chief Operating Officer and Medical Director. He began his professional career as a pioneer in Pediatric Emergency Medicine. His previous positions include work as a Principal Consultant with Health Management Associates, a national healthcare consulting firm. Greg started his career as a Pediatric Emergency Physician serving in leadership positions at two children’s hospitals and as administrative director of a medical group. 

He is a Fellow of the American College of Emergency Physicians and American Academy of Pediatrics. Greg has a passion for innovation, the expanded use of technology in healthcare, improving quality of care and heath equity.

Stephen Young

Stephen Young

CFO (Chief Financial Officer)

Stephen has 25 years of extensive experience in financial operations management in the consumer packaged goods industry.

He has successfully built and led finance teams with Del Monte Foods and Safeway, Inc. His passion for building financial operations from the ground up has led him from his recent start-up experiences to KOA ACCEL. Stephen’s expertise in economic analysis, strategic planning, and financial modeling has been instrumental to the successful launches of various new products domestically and internationally. He is also highly skilled in developing business processes, systems, and building financial/accounting infrastructure.

Stephen received his MBA degree from Southern Illinois University and both his B.S. degrees in Finance and Marketing from the University of Illinois at Urbana-Champaign

Arlene Bumb

Arlene Bumb

Head of Marketing

Arlene is a senior executive with over 30 years of experience in medical/healthcare marketing, business development, and management. Her areas of expertise include new product development and commercial launch (US and OUS); strategic and tactical marketing, market research, and product management; and, external communications.

She has played an integral part in the growth of large established companies, such as Pfizer (Shiley), Medtronic, Beckman-Coulter, St. Jude Medical, Thermo-Fischer, and most recently Arlene has focused on building the identity, value and infrastructure of many start-ups including EP Dynamics, Reviticell, Pegasus Biologics, PhageTech, BioMedGPS, and TinyKicks. Her consulting company, Silvergleid and Associates, has performed market due diligence for IPOs and advised international companies on the suitability for US market entry.

Arlene holds a BS in Chemistry and Biology from Simmons College and MBA courses from Boston University.

Stephane Gobron

Stephane Gobron

Head of Engineering

Stephane completed his Master of Plastic Engineering in France (INSA Strasbourg) before completing a second Master of Science in Chemical Engineering at Syracuse University (NY). To follow his interest in inventing new designs and products, he chose to work in the medical device industry, focusing on R&D and new product development. He is a highly accomplished medical device designer, with 31 device patents to his name spanning several medical fields of application: monitoring, ophthalmology, cardiology, implants, and minimally invasive endoscopic surgeries. 

Stephane has been working in the medical device Industry for over 25 years; he started in large cap , high-volume corporations (Boston Scientific, Novartis) to gradually focus onto the start-up world and develop his entrepreneurial business sense. He held various technical positions of increasing responsibilities and oversaw the development of several devices from concept definition to FDA clearance and market launch. He transitioned into executive management almost 15 years ago: leading technical teams, interacting with agencies, and helping with Venture Capital fund raising. 

Michelle Khine

Michelle Khine

Scientific Co-Founder & Director

Michelle Khine, Ph.D. is a Professor of Biomedical Engineering at UC Irvine. She is the founding Director of Faculty Innovation at the Samueli School of Engineering and founding Director of BioENGINE (BioEngineering Innovation and Entrepreneurship) at UC Irvine. Prior to joining UC Irvine in 2009, she was an Assistant & Founding Professor at UC Merced. Michelle received her BS and MS from UC Berkeley in Mechanical Engineering and her PhD in Bioengineering from UC Berkeley and UCSF. She is the Scientific Founder of 6 start-up companies. Michelle was the recipient of the TR35 Award and named one of Forbes ’10 Revolutionaries’ in 2009 and by Fast Company Magazine as one of the ‘100 Most Creative People in Business’ in 2011. She was awarded the NIH New Innovator’s Award, was named a finalist in the World Technology Awards for Materials, and was named by Marie‐Claire magazine as ‘Women on Top: Top Scientist’. She was named Innovator of the Year 2017 for the Samueli School of Engineering at UC Irvine. Michelle is a Fellow of AIMBE (American Institute of Medical and Biological Engineering, recognizing the top 2% of biomedical engineers nationally) and well as a Fellow of the National Academy of Inventors.

Anas Deiranieh

Anas Deiranieh


Anas received his B.S. degree in Biomedical Engineering from the University of California, Irvine. During his time at the University, he did research in Dr. Michelle Khine’s lab and developed a strong foundation in fabricating soft wearable electronics. After graduating, Anas joined Makani Science, where he spearheaded the protocol development and fabrication of the novel sensors used by the company. Anas also plays an instrumental role in the verification and validation testing of the Makani Science Respiratory Monitoring System.

Gracie Chan

Gracie Chan

Operations Coordinator

Gracie studied Business Management and Human Resources at Cal Poly Pomona. She is passionate about sustainability and social responsibility. While a student, she learned business management through various internships and campus involvements. She supports Makani Science by coordinating projects and programs. Gracie aids the team with resource, meeting, and information coordination. In addition, she helps oversee administrative and scheduling tasks.


Makani Science
Mar 31, 2023
$10k - $1.23M
Common Stock
Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

Most Recent Fiscal Year-End

Prior Fiscal Year-End

Total Assets



Cash & Cash Equivalents



Accounts Receivable



Short-Term Debt



Long-Term Debt



Revenue & Sales



Costs of Goods Sold



Taxes Paid



Net Income



*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing; provided, however, that the CEO’s ability to exercise the foregoing powers shall be conditioned upon the unanimous approval of the Board of Directors of the Company. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives and Bonuses*

Time-Based Perks

Friends and Family - First 7 days | 10% bonus shares

Super Early Bird - First 30 days | 5% bonus shares


Volume-Based Perks

Tier 1 Perk — Invest $500+ and receive 2% bonus shares

Tier 2 Perk — Invest $1000+ and receive 5% bonus shares

Tier 3 Perk — Invest $5,000+ and receive 10% bonus shares

Tier 4 Perk — Invest $10,000+ and receive 15% bonus shares

Tier 5 Perk — Invest $20,000+ and receive 20% bonus shares

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Makani Science will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any Common Stock shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $0.67 / share, you will receive 110 shares, meaning you'll own 110 shares for $67. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus in addition to the aforementioned bonus.

Irregular Use of Proceeds

We will not incur any irregular use of proceeds.


Article Image

Respiration rate and volume measurements using wearable strain sensors

Article Image
Youtube: University Lab Partners

Meet Makani Science

Article Image
Business Wire

Makani Science Receives $550,000 in Financing for Real-time Wireless Respiratory Sensor Patch Designed to Improve Sedation Safety

Article Image
Phys Org

Biomedical engineers develop wearable respiration monitor with children's toy

Article Image
Wearable Technologies

UCI Engineers Develop Wearable Respiration Sensors with Shrinky Dinks



Last Chance to Invest--Less than 1 Day!

Less than 1 Day to Invest!

Hi all,

This is your last chance to invest in Makani Science. Don't miss this opportunity and invest today!


Better Breathing, Better Health

Whether it's making sedated procedures safer, managing respiratory diseases, or potentially saving lives, the Makani Science Respiration Monitor can make a neglected vital sign more accessible to the world.

Invest Today! Join the movement toward better breathing.


Accepted into UC Launch

Hi everyone,

We are excited to announce that we've been selected to be a part of UC Launch, a highly selective accelerator within the University of California universities. We are one of 20 out of hundreds of applications that got chosen!

"LAUNCH is the University of California’s leading accelerator, designed to transform early-stage startups into fundable companies."

During Fall 2022, over 160+ companies raised over $725 million cumulatively. We look forward to growing and developing further through this program.


Notice of Material Change in Offering

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the Makani Science offering. Here's an excerpt describing the specifics of the change:

Campaign is extending their end date by 30 days

When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.


3 Important Facts about Breathing

Take a look at these 3 important facts about breathing!


Deadly Dentistry

One of our goals at Makani Science is to make sedation procedures safer. There is no doubt that medicine has improved greatly in the last couple of decades. However, there are still ways procedures could be made safer. Here’s an in-depth investigation Dallas Morning News published about safety concerns in the dental area:

We hope our breathing monitor can address some of these concerns!


Letter from the CEO

Hi everyone!

This is Michael Chu, CEO of Makani Science. I wanted to thank everyone for their continued support and, introduce myself in this update. I am originally from northern California but after graduating from UC San Diego with a degree in Bioengineering and getting my doctoral degree at UC Irvine, I am enjoying life in southern California. I am a co-inventor and one of the original founders of Makani Science. Most importantly I just got married this past year!

As the CEO for Makani Science, these are the values I approach the company with every day: 

• I believe in teamwork and respect – the team is key to the success of the company.

• Evidence-based science is important – data is key to showing that our product works. 

• I believe in earning the trust of our employees, customers, and investors - Trust is hard to earn and I strive to be a company of integrity.

I understand investing your hard-earned money into a startup can be a difficult choice, so please ask any questions you may have to help make the decision easier. My team and I are here to make sure you make the most informed decision possible. 

I truly appreciate your support and time and please stay safe and healthy!


Michael Chu


Breathing Article

Check out this link on how breathing can reduce stress!


Novel Sensor

Hi Everyone! I wanted to highlight the novel postage-size sensor used in our system. 

Instead of being rigid and hard, (like a circuit board) our sensors are soft and elastic, like a rubber band. This will make the sensor much more comfortable to wear and expands the market opportunity into other previously untapped fields.

Share this with someone who would be interested in a new type of sensor!


Early Bird Special

Our early bird special is about to expire in less than 5 days.

Take advantage of it now and get bonus shares!

Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!


Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Makani Science.



Hani Elshahawi


2 months ago

Interesting technology indeed. What price point do you anticipate at scale-$100 for single use may be OK for clinical settings but will be too high for remote patient monitoring (RPM) applications. Speaking of which, I have three more questions: 1) do you anticipate your biggest go-to-market to be in RPM? 2) Do you intend to add other sensing modalities or targets in the near-mid term or will you stay focused on breathing? 3) what has been the nature and form of your engagement with YC?



Richard Murray

4 months ago

When do you anticipate approval by the FDA or have you submitted your product to them yet? What's the lifespan of the wearable before replacement is recommended and the approximate cost of all consumables to the end user?



James Henley

5 months ago

Who is your competition? And what sets you apart from them? (Is anyone else working on a similar device that is different than current CPO and capnography?)



Jada Nix

5 months ago

Do you have any peer-reviewed manuscripts published on this technology?



Arthur Robertson

5 months ago

Are there any family members that are on staff that is related to any executive member. This makes me uncomfortable as an investor seeing that you could be just using the funds to give a job to support family.



Arthur Robertson

5 months ago

Do you have an actual product that has been tested and patented. Are there any actual uses currently during this phase and if so where and whos sing it now.




Cancel anytime before 48 hours before a rolling close or the offering end date.



We want you to succeed and get the most out of your money by offering rewards and memberships!


Your info is your info. We take pride in keeping it that way!


Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team



Important Message


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.

By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.